Topiramate may not increase risk of urolithiasis: A nationwide population-based cohort study

Ai Ling Shen; Hsiu Li Lin; Yuan Fu Tseng; Hsiu Chen Lin; Chien-Yeh Hsu; Che Yi Chou

doi:10.1016/j.seizure.2015.03.009

Topiramate may not increase risk of urolithiasis: A nationwide population-based cohort study

Ai Ling Shen, Hsiu Li Lin, Yuan Fu Tseng, Hsiu Chen Lin, Chien-Yeh Hsu, Che Yi Chou

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Purpose Topiramate is an effective anti-epileptic drug and can be associated with increased risk for urolithiasis because of its effects on acid-base profile. Evidences that supported an association of topiramate and urolithiasis were limited to case reports or series. We investigated the association of topiramate and urolithiasis in a nationwide population-based cohort study. Methods We analyzed 1377 patients receiving topiramate and 1377 age- and gender-matched control patients (not receiving topiramate) between 1997 and 2008. The risk of urolithiasis was analyzed using Kaplan-Meier analysis, followed by Cox proportional hazard regression. Results Of the 2754 patients, 79 (2.9%) patients developed urolithiasis in two (interquartile range: 1.2-4.2) years. The proportion of patients who developed urolithiasis in the patients receiving topiramate was not different from that of the control patients (p = 0.138, χ² test). The urolithiasis free survival was not different between the patients receiving topiramate and the control patients (p = 0.168) in Cox proportional hazard regression. The duration and total dosage of topiramate were not associated with risk of urolithiasis in patients receiving topiramate (p = 0.482 and p = 0.751). Conclusion Topiramate may not increase the risk of urolithiasis. The duration and the total dosage of topiramate were not associated with urolithiasis risks.

Original language	English
Pages (from-to)	86-89
Number of pages	4
Journal	Seizure
Volume	29
DOIs	https://doi.org/10.1016/j.seizure.2015.03.009
Publication status	Published - Jul 1 2015

Keywords

Health insurance database
Renal stone
Topiramate
Urolithiasis

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1016/j.seizure.2015.03.009

Cite this

@article{c43c4dbc5bc5489bb3e15c38f0881df6,

title = "Topiramate may not increase risk of urolithiasis: A nationwide population-based cohort study",

abstract = "Purpose Topiramate is an effective anti-epileptic drug and can be associated with increased risk for urolithiasis because of its effects on acid-base profile. Evidences that supported an association of topiramate and urolithiasis were limited to case reports or series. We investigated the association of topiramate and urolithiasis in a nationwide population-based cohort study. Methods We analyzed 1377 patients receiving topiramate and 1377 age- and gender-matched control patients (not receiving topiramate) between 1997 and 2008. The risk of urolithiasis was analyzed using Kaplan-Meier analysis, followed by Cox proportional hazard regression. Results Of the 2754 patients, 79 (2.9%) patients developed urolithiasis in two (interquartile range: 1.2-4.2) years. The proportion of patients who developed urolithiasis in the patients receiving topiramate was not different from that of the control patients (p = 0.138, χ2 test). The urolithiasis free survival was not different between the patients receiving topiramate and the control patients (p = 0.168) in Cox proportional hazard regression. The duration and total dosage of topiramate were not associated with risk of urolithiasis in patients receiving topiramate (p = 0.482 and p = 0.751). Conclusion Topiramate may not increase the risk of urolithiasis. The duration and the total dosage of topiramate were not associated with urolithiasis risks.",

keywords = "Health insurance database, Renal stone, Topiramate, Urolithiasis",

author = "Shen, {Ai Ling} and Lin, {Hsiu Li} and Tseng, {Yuan Fu} and Lin, {Hsiu Chen} and Chien-Yeh Hsu and Chou, {Che Yi}",

note = "Funding Information: We thank the National Health Research Institute in Taiwan for providing the insurance claims data. This study was supported in part by the Executive Yuan National Science Council (grant number NSC 98-2621-M-039-001 ), Clinical Trial and Research Center of Excellence of the Department of Health (grant number DOH101-TD-B-111-004 ), Taiwan Department of Health Cancer Research Center of Excellence (grant number DOH101-TD-C-111-005 ) and the China Medical University Hospital (grant number 1MS1 ). Publisher Copyright: {\textcopyright} 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.",

year = "2015",

month = jul,

day = "1",

doi = "10.1016/j.seizure.2015.03.009",

language = "English",

volume = "29",

pages = "86--89",

journal = "Seizure : the journal of the British Epilepsy Association",

issn = "1059-1311",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Topiramate may not increase risk of urolithiasis

T2 - A nationwide population-based cohort study

AU - Shen, Ai Ling

AU - Lin, Hsiu Li

AU - Tseng, Yuan Fu

AU - Lin, Hsiu Chen

AU - Hsu, Chien-Yeh

AU - Chou, Che Yi

N1 - Funding Information: We thank the National Health Research Institute in Taiwan for providing the insurance claims data. This study was supported in part by the Executive Yuan National Science Council (grant number NSC 98-2621-M-039-001 ), Clinical Trial and Research Center of Excellence of the Department of Health (grant number DOH101-TD-B-111-004 ), Taiwan Department of Health Cancer Research Center of Excellence (grant number DOH101-TD-C-111-005 ) and the China Medical University Hospital (grant number 1MS1 ). Publisher Copyright: © 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Purpose Topiramate is an effective anti-epileptic drug and can be associated with increased risk for urolithiasis because of its effects on acid-base profile. Evidences that supported an association of topiramate and urolithiasis were limited to case reports or series. We investigated the association of topiramate and urolithiasis in a nationwide population-based cohort study. Methods We analyzed 1377 patients receiving topiramate and 1377 age- and gender-matched control patients (not receiving topiramate) between 1997 and 2008. The risk of urolithiasis was analyzed using Kaplan-Meier analysis, followed by Cox proportional hazard regression. Results Of the 2754 patients, 79 (2.9%) patients developed urolithiasis in two (interquartile range: 1.2-4.2) years. The proportion of patients who developed urolithiasis in the patients receiving topiramate was not different from that of the control patients (p = 0.138, χ2 test). The urolithiasis free survival was not different between the patients receiving topiramate and the control patients (p = 0.168) in Cox proportional hazard regression. The duration and total dosage of topiramate were not associated with risk of urolithiasis in patients receiving topiramate (p = 0.482 and p = 0.751). Conclusion Topiramate may not increase the risk of urolithiasis. The duration and the total dosage of topiramate were not associated with urolithiasis risks.

AB - Purpose Topiramate is an effective anti-epileptic drug and can be associated with increased risk for urolithiasis because of its effects on acid-base profile. Evidences that supported an association of topiramate and urolithiasis were limited to case reports or series. We investigated the association of topiramate and urolithiasis in a nationwide population-based cohort study. Methods We analyzed 1377 patients receiving topiramate and 1377 age- and gender-matched control patients (not receiving topiramate) between 1997 and 2008. The risk of urolithiasis was analyzed using Kaplan-Meier analysis, followed by Cox proportional hazard regression. Results Of the 2754 patients, 79 (2.9%) patients developed urolithiasis in two (interquartile range: 1.2-4.2) years. The proportion of patients who developed urolithiasis in the patients receiving topiramate was not different from that of the control patients (p = 0.138, χ2 test). The urolithiasis free survival was not different between the patients receiving topiramate and the control patients (p = 0.168) in Cox proportional hazard regression. The duration and total dosage of topiramate were not associated with risk of urolithiasis in patients receiving topiramate (p = 0.482 and p = 0.751). Conclusion Topiramate may not increase the risk of urolithiasis. The duration and the total dosage of topiramate were not associated with urolithiasis risks.

KW - Health insurance database

KW - Renal stone

KW - Topiramate

KW - Urolithiasis

UR - http://www.scopus.com/inward/record.url?scp=84930980720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930980720&partnerID=8YFLogxK

U2 - 10.1016/j.seizure.2015.03.009

DO - 10.1016/j.seizure.2015.03.009

M3 - Article

C2 - 26076848

AN - SCOPUS:84930980720

SN - 1059-1311

VL - 29

SP - 86

EP - 89

JO - Seizure : the journal of the British Epilepsy Association

JF - Seizure : the journal of the British Epilepsy Association

ER -

Topiramate may not increase risk of urolithiasis: A nationwide population-based cohort study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this